GT Biopharma announced it has submitted an IND to the FDA for GTB-5550, its third NK cell engager entering clinical development for B7-H3–expressing solid tumors, while reporting a strengthen
GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 anticipated to extend...
Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – The 2025 American Society of Hematology meeting showcased pivotal advances in blood cancer treatment, with...
Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Scientists have engineered breakthrough cell therapies that can be mass-produced and stored ready-to-use, addressing...
Phase 1 trial evaluating GTB-3650 TriKE ® for relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues to actively enroll with the next update anticipated in Q1 2026...
Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Scientists engineered invisible immune cells in October 2025 that hide from rejection while destroying tumors[1],...
Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Biomarker-driven approaches enhance the likelihood of identifying optimal patient populations and streamline...
Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – The convergence of advanced diagnostics and targeted therapeutics is reshaping cancer care, as September 2025...
Today announced that enrollment in the dose escalation cohorts of the Phase 1 trial, evaluating GTB-3650 ...
Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Researchers at Ohio State University just unlocked why many cancer immunotherapies fail, identifying a protein...